CTEPH: Where Are We and the Future

21 Nov 2026 11:50 12:15
Luis Jara-Palomares Speaker Spain
Chronic thromboembolic pulmonary hypertension (CTEPH) is a potentially treatable cause of pulmonary hypertension characterised by persistent organised pulmonary arterial obstruction and secondary microvascular remodelling. Despite advances in management, delayed recognition and unequal access to expert care remain important challenges. This presentation reviews the contemporary diagnostic and therapeutic pathway, integrating guideline recommendations with evidence from clinical trials and international registries. Persistent dyspnoea or exercise limitation after pulmonary embolism should prompt structured assessment, while the absence of a recognised embolic event does not exclude CTEPH. Ventilation–perfusion imaging, anatomical assessment and right heart catheterisation provide complementary information for diagnosis and treatment planning. Multidisciplinary evaluation is central to selecting pulmonary endarterectomy, balloon pulmonary angioplasty and medical therapy. Lifelong therapeutic anticoagulation remains essential, although uncertainty persists regarding the optimal anticoagulant for patients without antiphospholipid syndrome. Symptomatic chronic thromboembolic pulmonary disease without resting pulmonary hypertension requires careful symptom attribution and individualised treatment decisions. Future developments include circulating biomarkers, novel therapies targeting vascular remodelling and artificial intelligence for earlier detection, complication prediction and phenotyping. Multimodal models integrating clinical, biochemical and imaging data could support diagnostic testing and referral decisions, but require external validation and prospective demonstration of clinical benefit. Earlier recognition, timely expert referral and individualised multimodal care remain the priorities for improving outcomes.